30-MAY-2023 6:10

LYMPH ACCRUAL REPORT - Open and Recently Closed Studies

SWOG/
Support		 STUDY R
E
G		 O
P
E
N		 ARM ACCR.
GOAL		 TOTAL
REGS.		 REGS.
LAST
12
Month		 REGS.
LAST
6
Month		 REGS.
LAST
3
Month		 REGS.
LAST
30
DAYS		 REGS.
LAST
7
DAYS		 DATE OF
FIRST
REG.		 # of
ACT.
INSTs		 # of
CURR
IRBs
SWOG S1608-FL, TGR-1202/Lenalidomide/CHOP or Benda +Ob 1 Y 1 TGR-1202 + Obinutuzumab 95 26 0 0 0 0 0 01/23/2018 207 76
        2 Lenalidomide + Obinutuzumab   25 1 1 1 0 0      
        3 CHOP + Obinutuzumab   11 0 0 0 0 0      
        4 Bendamustine + Obinutuzumab   11 0 0 0 0 0      
            73 1 1 1 0 0      
 
  S1918-DLBCL, Adv, Age 75+, CC-486 +/- R-miniCHOP 1 Y 1 CC-486 + R-miniCHOP 422 30 14 4 4 3 0 05/25/2021 170 70
        2 R-miniCHOP   26 11 4 4 1 0      
            56 25 8 8 4 0      
 
Yes E4412-HD, RR, Ipilimumab +Nivo +Brentuximab Vedotin 1 E Total Registrations   20 0 0 0 0 0 04/17/2019 106 65
            20 0 0 0 0 0      
 
  EA4151-Lymph, AHCT +/-Ritux, MRD Neg 0 E Total Registrations   145 14 12 7 1 1 04/03/2018 214 83
            145 14 12 7 1 1      
 
    1 E Total Registrations   115 17 10 6 1 0 04/03/2018    
            115 17 10 6 1 0      
 
  EA4181-MCL, Randomization BR/CR v BR/CR-A v BR-A 1 E Total Registrations   73 12 5 3 0 0 12/13/2019 189 81
            73 12 5 3 0 0      
 
No A051701-LYMPH, MYC/BC2 DHL&DEL, R-chemo+/-Venetoclax 1 T Total Registrations   34 0 0 0 0 0 01/02/2020 248 99
            34 0 0 0 0 0      
 
  ANHL1931-PMBCL, Chemo-Immunotherapy +/- Nivo 1 E Total Registrations   9 8 5 2 0 0 02/28/2022 202 105
            9 8 5 2 0 0      
 
  E4402- 2 E Total Registrations   3 0 0 0 0 0 11/09/2004    
            3 0 0 0 0 0      
 
  E4402-NHL, Low Tumor, Compare Rituximab Dosing 1 E Total Registrations   5 0 0 0 0 0 11/09/2004    
            5 0 0 0 0 0      
 

30-MAY-2023 6:10

LYMPH Open Studies with No Registrations

Study Registration/Phase Open Date # of
ACT.
INSTs		 # of
CURR
IRBs
S2114 NHL, Rel/Ref, CD19 CAR-T +/- Consolidation 1 Initial Registration 23-Feb-23 73 21
  2 Randomization 23-Feb-23 73 21
  3 Crossover 23-Feb-23 73 21